Dicycloverine 20mg tablets

国家: 英国

语言: 英文

来源: MHRA (Medicines & Healthcare Products Regulatory Agency)

有效成分:

Dicycloverine hydrochloride

可用日期:

Flamingo Pharma (UK) Ltd

ATC代码:

A03AA07

INN（国际名称）:

Dicycloverine hydrochloride

剂量:

20mg

药物剂型:

Oral tablet

给药途径:

Oral

类:

No Controlled Drug Status

处方类型:

Valid as a prescribable product

產品總結:

BNF: 01020000; GTIN: 5060464501746

产品特点

OBJECT 1
Dicycloverine 20 mg Tablets
Summary of Product Characteristics Updated 16-Jun-2021 | Flamingo
Pharma (UK) Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Dicycloverine Hydrochloride 20 mg Tablets
2. Qualitative and quantitative composition
Each tablet contains 20 mg of Dicycloverine hydrochloride.
Excipient(s) with known effect:
Each tablet contains 134.00 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablet
White to off white, circular, flat beveled edge uncoated tablet
debossed with “S” and “20” separated by
break-line on one side and plain on other side.
The score line is only to facilitate breaking for ease of swallowing
and not to divide into equal doses.
4. Clinical particulars
4.1 Therapeutic indications
Smooth muscle antispasmodic primarily indicated for treatment of
functional conditions involving smooth
muscle spasm of the gastrointestinal tract.
4.2 Posology and method of administration
Po